---
title: "Priority use cases for tuberculosis biomarkers and tests across infection, disease, treatment and"
id: "medrxiv-20-defining-use-cases-for-biomarkers-and-tests-across-tuberculosis-infection"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-20-defining-use-cases-for-biomarkers-and-tests-across-tuberculosis-infection"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.01.26361598v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Priority use cases for tuberculosis biomarkers and tests across infection, disease, treatment and
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-20-defining-use-cases-for-biomarkers-and-tests-across-tuberculosis-infection
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.01.26361598v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This international consensus exercise aimed to define, validate, and prioritise use cases for **tuberculosis** biomarkers and diagnostic tests across the full care pathway: **Mtb infection**, active disease, treatment optimisation, and post‑TB care. - A scoping review of literature, guidelines, and target product profiles (24 documents) generated 69 candidate use cases, which were consolidated to 13 for the consensus process. - A hybrid RAND/UCLA modified Delphi process engaged 185 identified interest‑holders from clinical, research, industry, policy, funding, civil society and national programme backgrounds, including WHO representatives. - Participants completed an online survey rating agreement with each use case; use cases with <80% agreement were discussed in a consensus meeting, followed by a validation meeting. - The process retained eleven use cases spanning four stages: three for **Mtb infection**, four for disease detection, three for treatment optimisation, and one for post‑TB care. - Highest‑priority use cases identified were detection of **drug‑resistant TB**, prediction of progression from infection to disease, identification of current **Mtb infection**, and improved diagnosis of **active TB disease**. - The authors conclude this is the first comprehensive, prioritised framework of use cases to guide investment, focus biomarker discovery, inform target product profiles, funding calls and policy development. - The study recommends applying this framework to the existing biomarker pipeline to identify gaps between innovation and priority needs. - Ethical considerations: formal IRB approval was not required as the consensus methods collected anonymised professional input; no new patient data were generated. - Funding: Wellcome Trust supported the work.
## Clinical Analysis & Structured Key Points
Defining use cases for biomarkers and tests across tuberculosis infection, disease and treatment: An international consensus and prioritisation exercise | medRxiv Skip to main content Defining use cases for biomarkers and tests across tuberculosis infection, disease and treatment: An international consensus and prioritisation exercise View ORCID Profile Sacha Wright , View ORCID Profile Federico Fama , Angus de Wilton , View ORCID Profile Ellen Steward , Francesca Saluzzo , Chiara Sepulcri , View ORCID Profile James Greenan-Barrett , View ORCID Profile Khay Mar Aung , Thi Mai Nguyen , View ORCID Profile Nora Engel , View ORCID Profile Seda Yerlikaya , Hanif Esmail , Salome Charalambous , Cecily Miller , Ruvandhi Nathavitharana , View ORCID Profile Luan Nguyen Quang Vo , Mikashmi Kohli , View ORCID Profile Delia Goletti , View ORCID Profile Daniela Cirillo , View ORCID Profile Mahdad Noursadeghi , Claudia Maria Denkinger , View ORCID Profile Emily Lai-Ho MacLean , View ORCID Profile Rishi K Gupta , View ORCID Profile Ankur Gupta-Wright doi: https://doi.org/10.64898/2026.09.01.26361598 Sacha Wright 1 University College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sacha Wright Federico Fama 1 University College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Federico Fama Angus de Wilton 2 University of Bristol; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ellen Steward 1 University College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ellen Steward Francesca Saluzzo 3 Scientific Institute San Raffaele: IRCCS Ospedale San Raffaele; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Chiara Sepulcri 3 Scientific Institute San Raffaele: IRCCS Ospedale San Raffaele; Find this author on Google Scholar Find this author on PubMed Search for this author on this site James Greenan-Barrett 1 University College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for James Greenan-Barrett Khay Mar Aung 4 The University of Sydney; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Khay Mar Aung Thi Mai Nguyen 4 The University of Sydney; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nora Engel 5 Vrije Universiteit Amsterdam; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nora Engel Seda Yerlikaya 6 Heidelberg University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Seda Yerlikaya Hanif Esmail 1 University College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Salome Charalambous 7 University of the Witwatersrand Johannesburg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cecily Miller 8 World Health Organization; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ruvandhi Nathavitharana 9 Harvard Medical School; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Luan Nguyen Quang Vo 10 Karolinska Institutet; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Luan Nguyen Quang Vo Mikashmi Kohli 11 Foundation for Innovative New Diagnostics: FIND; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Delia Goletti 12 Istituto Nazionale per le Malattie Infettive: Istituto Nazionale Malattie Infettive Lazzaro Spallanzani; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Delia Goletti Daniela Cirillo 3 Scientific Institute San Raffaele: IRCCS Ospedale San Raffaele; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Daniela Cirillo Mahdad Noursadeghi 1 University College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mahdad Noursadeghi Claudia Maria Denkinger 6 Heidelberg University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Emily Lai-Ho MacLean 4 The University of Sydney; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Emily Lai-Ho MacLean Rishi K Gupta 1 University College London; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Rishi K Gupta Ankur Gupta-Wright 13 Imperial College London / North Bristol NHS Trust / University of Heidelberg Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ankur Gupta-Wright For correspondence: a.gupta-wright{at}imperial.ac.uk Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background Translation of tuberculosis (TB) biomarker and diagnostic research into tools that improve patient and public health outcomes has been slow, partly because no internationally agreed framework exists defining the use cases that new biomarkers and tests should address. We aimed to identify, validate, and prioritise use cases for TB biomarkers and tests across Mycobacterium tuberculosis (Mtb) infection, TB disease, TB treatment, and post-TB care, through an international consensus process. Methods and Findings We conducted a scoping review of the literature, guidelines, and target product profiles (24 documents; 69 candidate use cases consolidated to 13), followed by a hybrid RAND/UCLA modified Delphi consensus process involving 185 identified interest-holders, including clinicians, researchers, diagnostic developers, industry, funders, civil society, national TB programmes, and policymakers (including WHO representatives). Interest-holders completed an online survey rating agreement with each use case, and attended a consensus meeting to discuss use cases with less than 80% agreement, followed by a further validation meeting. Eleven use cases were retained across four TB care pathway stages: three for Mtb infection, four for disease detection, three for treatment optimisation, and one for post-TB care. Highest-priority use cases were detection of drug-resistant TB, prediction of progression from infection to disease, identification of current Mtb infection, and improved diagnosis of active TB disease. Conclusions This consensus exercise provides the first comprehensive, prioritised framework of use cases for TB biomarkers and tests, spanning the full care pathway. These eleven priority use cases can guide investment, focus biomarker discovery, and inform future target product profiles, funding calls, and policy development. Applying the framework to the current biomarker pipeline is a key next step to address gaps between innovation and priority needs. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study involved a scoping review, anonymous survey, and structured consensus process with interest-holders. In line with published guidance on consensus methods, formal ethical approval was not required as participants contributed in a professional capacity no identifiable, sensitive personal data were collected and responses were anonymized. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability No data was generated by this study. Funder Information Declared Wellcome Trust, https://ror.org/029chgv08 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 04, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Defining use cases for biomarkers and tests across tuberculosis infection, disease and treatment: An international consensus and prioritisation exercise Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Defining use cases for biomarkers and tests across tuberculosis infection, disease and treatment: An international consensus and prioritisation exercise Sacha Wright , Federico Fama , Angus de Wilton , Ellen Steward , Francesca Saluzzo , Chiara Sepulcri , James Greenan-Barrett , Khay Mar Aung , Thi Mai Nguyen , Nora Engel , Seda Yerlikaya , Hanif Esmail , Salome Charalambous , Cecily Miller , Ruvandhi Nathavitharana , Luan Nguyen Quang Vo , Mikashmi Kohli , Delia Goletti , Daniela Cirillo , Mahdad Noursadeghi , Claudia Maria Denkinger , Emily Lai-Ho MacLean , Rishi K Gupta , Ankur Gupta-Wright medRxiv 2026.09.01.26361598; doi: https://doi.org/10.64898/2026.09.01.26361598 Share This Article: Copy Citation Tools Defining use cases for biomarkers and tests across tuberculosis infection, disease and treatment: An international consensus and prioritisation exercise Sacha Wright , Federico Fama , Angus de Wilton , Ellen Steward , Francesca Saluzzo , Chiara Sepulcri , James Greenan-Barrett , Khay Mar Aung , Thi Mai Nguyen , Nora Engel , Seda Yerlikaya , Hanif Esmail , Salome Charalambous , Cecily Miller , Ruvandhi Nathavitharana , Luan Nguyen Quang Vo , Mikashmi Kohli , Delia Goletti , Daniela Cirillo , Mahdad Noursadeghi , Claudia Maria Denkinger , Emily Lai-Ho MacLean , Rishi K Gupta , Ankur Gupta-Wright medRxiv 2026.09.01.26361598; doi: https://doi.org/10.64898/2026.09.01.26361598 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Public and Global Health Subject Areas All Articles Addiction Medicine (615) Allergy and Immunology (896) Anesthesia (327) Cardiovascular Medicine (4775) Dentistry and Oral Medicine (476) Dermatology (410) Emergency Medicine (644) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1616) Epidemiology (15852) Forensic Medicine (32) Gastroenterology (1196) Genetic and Genomic Medicine (6993) Geriatric Medicine (727) Health Economics (1058) Health Informatics (4998) Health Policy (1428) Health Systems and Quality Improvement (1741) Hematology (583) HIV/AIDS (1337) Infectious Diseases (except HIV/AIDS) (16248) Intensive Care and Critical Care Medicine (1162) Medical Education (664) Medical Ethics (151) Nephrology (721) Neurology (7205) Nursing (365) Nutrition (1074) Obstetrics and Gynecology (1233) Occupational and Environmental Health (1002) Oncology (3581) Ophthalmology (1038) Orthopedics (393) Otolaryngology (448) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1780) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5843) Public and Global Health (9705) Radiology and Imaging (2391) Rehabilitation Medicine and Physical Therapy (1436) Respiratory Medicine (1245) Rheumatology (635) Sexual and Reproductive Health (769) Sports Medicine (577) Surgery (768) Toxicology (107) Transplantation (303) Urology (286)
## Related Clinical Research

- [Urine-based Mtb antigen detection for childhood TB using an ultrasensitive ECL immunoassay](https://medichelpline.com/clinical-feed/medrxiv-16-the-accuracy-of-urine-based-mycobacterial-antigens-to-detect-childhood.md)
- [Determinants of Favorable MDR-TB Treatment Outcomes in Zambia, 2018–2022](https://medichelpline.com/clinical-feed/plos-one-16-determinants-of-favorable-treatment-outcomes-in-multidrug-resistant.md)
- [Predictors of Healthcare Costs for Commercially Insured Adults with Tuberculosis in the US (2013–2](https://medichelpline.com/clinical-feed/medrxiv-0-predictors-of-healthcare-costs-among-commercially-insured-persons-with.md)
- [Epidemiology and species-level susceptibility of Candida infections in a Tolima tertiary hospital](https://medichelpline.com/clinical-feed/plos-one-4-clinical-and-microbiological-epidemiology-of-candida-infections-in-a-high.md)
- [Gut microbiota and tuberculosis: article content not provided—metadata and access details](https://medichelpline.com/clinical-feed/frontiers-in-immunology-14-gut-microbiota-driven-immunomodulation-in-tuberculosis-targeting-dysbiosis-to.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.